Microbot Medical Stock

Microbot Medical P/S

(Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. of Microbot Medical (MBOT) as of Jul 27, 2026.

P/S

0.00

Last updated:

As of Jul 27, 2026, Microbot Medical's P/S ratio stood at 0.00, a % change from the 0.00 P/S ratio recorded in the previous year.

The Microbot Medical P/S history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/S
Date
P/S
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023
0.00 base
Jan 1, 2024
0.00 base
Jan 1, 2025
0.00 base
Jan 1, 2026 (e)
34.26 base
YEARP/S
2026 est 34.26
2025 -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 74.17
2014 12.00
2013 10.44
2012 8.57
2011 2.91
2010 11.49
2009 16.74
2008 62.56
2007 139.45
2006 144.48
Access this data via the Eulerpool API

Microbot Medical Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Microbot Medical's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Microbot Medical's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Microbot Medical's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Microbot Medical grows earnings faster than its peers.

Microbot Medical Stock analysis

What does Microbot Medical do? Microbot Medical Inc. is a leading company in the development of microrobots for the medical field. The company was established in 2010 and is headquartered in Hingham, Massachusetts. Microbot Medical Inc. believes that the future of medicine lies in robotics and specializes in developing innovative solutions for complex surgical procedures and minimally invasive interventions. The company's business model is based on the development and commercialization of intelligent microrobots that will enable more precise and gentle surgical interventions. From the beginning, the company has focused on two main areas: the development of robot-assisted systems for neurosurgical procedures and the development of solutions for gastroenterology applications. In the field of neurosurgical procedures, Microbot Medical Inc. has developed the LIBERTY robot for market readiness. This robot is designed to assist surgeons during neurosurgical procedures that require increased precision and effectiveness. The robot aids the surgeon in navigating difficult-to-access areas of the brain and can help minimize the risk of tissue damage. Microbot Medical Inc. is also a leader in the development of robots in the gastroenterology field. The company has introduced the SELF-TESTER robot, which is capable of performing endoscopies in a more comfortable and painless manner. The SELF-TESTER is navigated through the digestive system and can help diagnose diseases such as cancer or inflammations in the gastrointestinal tract more effectively. Furthermore, Microbot Medical Inc. conducts research and development activities in the field of cardiovascular surgery. The company is working on a solution that allows doctors to implant aortic valves minimally invasively. The goal is to create an alternative to traditional open-heart surgery. The company has also signed a letter of intent with Cardiovascular Systems Inc. to jointly bring a new product to market that has the potential to further accelerate the minimally invasive aortic valve implantation procedure. In recent years, Microbot Medical Inc. has received several awards and recognitions, including an award from Frost & Sullivan in the category of "New Product Innovation." The company has also formed important partnerships with other leaders in the medical technology field to support the development and commercialization of its products. In conclusion, Microbot Medical Inc. is one of the leading providers of intelligent robots for the medical field and will play an important role in the development of advanced technologies that contribute to making surgical interventions more effective and safer in the coming years. The company is committed to driving innovations in medical technology and has already made a name for itself by successfully developing products in various areas. Microbot Medical is one of the most popular companies on Eulerpool.

P/S Details

Decoding Microbot Medical's P/S Ratio

Microbot Medical's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Microbot Medical's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Microbot Medical's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Microbot Medical’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Microbot Medical stock

On Eulerpool you can find the complete historical development of (Price-Sales Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the revenue per share. The P/S indicates how many years a company needs to generate the revenue per share as profit. A low P/S suggests that a stock may be undervalued, while a high P/S could indicate overvaluation. However, it is important to always consider the P/S in the context of the industry and the company. Microbot Medical since 2006 – with annual values, charts, and detailed analysis.

The P/S ratio when valuing a stock.

The price-to-sales ratio (P/S ratio) is an important tool of technical analysis that assists investors in evaluating stocks. It refers to the earnings per share of a company and its price movements. This indicator can be used to determine a stock's fair value, relative to the company's earnings.

History of the Price-to-Sales Ratio

The price-to-sales ratio is a relatively new indicator. It was first used in the 1980s by John Price when he developed the Price-to-Sales Index (PSI). Price wanted to find a way to value stocks taking into account their earnings. He noticed that many stock prices were not in line with their earnings situation. The PSI has since become an important analytical tool and is often referred to as the P/S ratio.

Calculation of the price-to-sales ratio

The price-to-sales ratio is easy to calculate. It is determined by dividing the current stock price by the company's earnings per share. P/S ratio = Stock price / Earnings per share. For example, if a company's stock price is $10 and the earnings per share is $2, then the P/S ratio is 5.

Application of the Price-to-Sales Ratio

The Price-to-Sales ratio is a useful tool for determining a fairly valued stock price. A low P/S ratio may indicate that a stock price is undervalued, which could be a good entry opportunity. However, a high Price-to-Sales ratio may indicate that a stock price is overvalued and investors should exercise caution.

An example: A company has a stock price of 20 USD and an earnings per share of 2 USD. The P/E ratio is 10. This could indicate that the stock price is overvalued and investors should be cautious before buying.

Investors and the price-to-sales ratio

Investors use the price-to-sales ratio to determine whether a company's stock price is fairly valued or not. They can compare the P/S ratio to see how the stock price relates to the company's earnings. Investors can also observe the P/S ratio over a longer period of time to see if the stock price changes in relation to the company's earnings.

Advantages and Disadvantages of the Price-to-Sales Ratio

The greatest advantage of the price-to-sales ratio is that it is a simple and understandable tool to determine the fair value of a stock price. It can also help investors identify stocks that are undervalued. One disadvantage is that the P/S ratio does not provide information about the company's profits. Therefore, investors should also consider other financial ratios before investing.

In today's time, the price-to-sales ratio is an important tool for investors to evaluate stocks and identify potential investment opportunities. It can help find a fairly valued stock price and identify stocks that are undervalued. However, investors should also consider other financial indicators before making an investment decision.

Access this data via the Eulerpool API

Valuation — Microbot Medical

All Key Metrics — Microbot Medical